OBJECTIVE: To evaluate in vitro and in vivo the efficacy of covalent end point-attached heparin to single-lumen polyurethane central venous catheters in reducing microbial adherence and colonization. DESIGN: In vitro study: A controlled bench study. In vivo study: A prospective, randomized, double-blind, clinical trial. SETTING:Intensive care unit in a 1200-bed teaching hospital. INTERVENTIONS: In vitro study: Adhesion of 17 radiolabeled clinical isolates of Staphylococci to catheters was examined in vitro. In vivo study: The outcome of heparinized and control catheters was compared in vivo in patients receiving long-term parenteral nutrition. Fifty-five adult patients were prospectively, blindly randomized to heparinized or control central venous catheters. The catheters, removed on clinical grounds, were analyzed with semiquantitative and quantitative cultures. Blood cultures were done at catheter removal. MEASUREMENTS AND MAIN RESULTS: In vitro study: Coagulase-negative Staphylococci adhered less in vitro to heparinized catheters than to control catheters (p < .05). In vivo study: Among 32 central venous catheters, or patients who completed the study, catheter-associated bacteremia or fungemia was observed in five patients in the control group (n = 19) and in no patient with a heparinized catheter (n = 13) (p = .047). Four of 13 catheters in the heparin group were colonized compared with 14 of 19 in the control group (p = .03). Coagulase-negative Staphylococci were the most frequent microorganisms in both groups. The numbers of organisms found on colonized catheters were larger in the control group than in the heparin group. CONCLUSIONS: Covalent end point surface heparinization appears to have a great impact on both in vitro and in vivo bacterial colonization of central venous catheters. Such heparinization can be a practical and economical approach to the prevention of catheter-associated bacteremia or fungemia.
RCT Entities:
OBJECTIVE: To evaluate in vitro and in vivo the efficacy of covalent end point-attached heparin to single-lumen polyurethane central venous catheters in reducing microbial adherence and colonization. DESIGN: In vitro study: A controlled bench study. In vivo study: A prospective, randomized, double-blind, clinical trial. SETTING: Intensive care unit in a 1200-bed teaching hospital. INTERVENTIONS: In vitro study: Adhesion of 17 radiolabeled clinical isolates of Staphylococci to catheters was examined in vitro. In vivo study: The outcome of heparinized and control catheters was compared in vivo in patients receiving long-term parenteral nutrition. Fifty-five adult patients were prospectively, blindly randomized to heparinized or control central venous catheters. The catheters, removed on clinical grounds, were analyzed with semiquantitative and quantitative cultures. Blood cultures were done at catheter removal. MEASUREMENTS AND MAIN RESULTS: In vitro study: Coagulase-negative Staphylococci adhered less in vitro to heparinized catheters than to control catheters (p < .05). In vivo study: Among 32 central venous catheters, or patients who completed the study, catheter-associated bacteremia or fungemia was observed in five patients in the control group (n = 19) and in no patient with a heparinized catheter (n = 13) (p = .047). Four of 13 catheters in the heparin group were colonized compared with 14 of 19 in the control group (p = .03). Coagulase-negative Staphylococci were the most frequent microorganisms in both groups. The numbers of organisms found on colonized catheters were larger in the control group than in the heparin group. CONCLUSIONS: Covalent end point surface heparinization appears to have a great impact on both in vitro and in vivo bacterial colonization of central venous catheters. Such heparinization can be a practical and economical approach to the prevention of catheter-associated bacteremia or fungemia.
Authors: Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint Journal: Clin Infect Dis Date: 2011-04-01 Impact factor: 9.079
Authors: Elizabeth J Brisbois; Maria Kim; Xuewei Wang; Azmath Mohammed; Terry C Major; Jianfeng Wu; Jessica Brownstein; Chuanwu Xi; Hitesh Handa; Robert H Bartlett; Mark E Meyerhoff Journal: ACS Appl Mater Interfaces Date: 2016-10-21 Impact factor: 9.229
Authors: H P Loveday; J A Wilson; R J Pratt; M Golsorkhi; A Tingle; A Bak; J Browne; J Prieto; M Wilcox Journal: J Hosp Infect Date: 2014-01 Impact factor: 3.926
Authors: M N Carrasco; A Bueno; C de las Cuevas; S Jimenez; I Salinas; A Sartorius; T Recio; M Generelo; F Ruiz-Ocaña Journal: Intensive Care Med Date: 2004-01-13 Impact factor: 17.440